NN 9926

Drug Profile

NN 9926

Alternative Names: GLP-1 SG GIPET; Long-acting GLP-1 analogue; NN-9926; NNC 0113-0987; Non-invasive GLP-1 - Novo Nordisk; OG-987-GT; Oral GLP-1 987 C10; SG GIPET

Latest Information Update: 03 Sep 2014

Price : $50

At a glance

  • Originator Novo Nordisk
  • Class Antihyperglycaemics
  • Mechanism of Action Glucagon like peptide 1 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Type 2 diabetes mellitus

Most Recent Events

  • 01 Jul 2014 Novo Nordisk completes a phase I trial in Healthy volunteers in United Kingdom (NCT02094521)
  • 01 Jun 2014 Novo Nordisk completes a phase I trial in Healthy volunteers in Germany (NCT01978613)
  • 01 May 2014 Novo Nordisk completes a phase I trial in Healthy volunteers in United Kingdom (NCT01967589)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top